Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma

NCT06892054 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)

Sponsor

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Collaborators

Apices Soluciones S.L.
GERCOR - Multidisciplinary Oncology Cooperative Group